市場調查報告書

肽受體放射性核素治療(PRRT)的全球市場:市場規模·佔有率·預測·市場機會

Peptide Receptor Radionuclide Therapy Market, by Drug Type (Lutetium -based), by Disease Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 924629
出版日期 內容資訊 英文 127 Pages
商品交期: 2-3個工作天內
價格
肽受體放射性核素治療(PRRT)的全球市場:市場規模·佔有率·預測·市場機會 Peptide Receptor Radionuclide Therapy Market, by Drug Type (Lutetium -based), by Disease Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年01月14日內容資訊: 英文 127 Pages
簡介

本報告提供全球肽受體放射性核素治療(PRRT)市場調查,提供市場概要,各醫藥品類型·適應症·流通管道·各地區的市場規模的變化與預測,市場成長要素及阻礙因素,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場摘要:各醫藥品類型
    • 市場摘要:各適應症
    • 市場摘要:各流通管道
    • 市場摘要:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態·規定·趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 合併·收購
  • 法規方案
  • 償付方案
  • PEST分析

第4章 全球肽受體放射性核素治療(PRRT)市場:各醫藥品類型

  • 簡介
  • 鎦(Lu-177)為主

第5章 全球肽受體放射性核素治療(PRRT)市場:各適應症

  • 簡介
  • 胰臟 - 神經內分泌腫瘤
  • 消化管 - 神經內分泌腫瘤
  • 其他

第6章 全球肽受體放射性核素治療(PRRT)市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局

第7章 全球肽受體放射性核素治療(PRRT)市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 企業簡介
    • Novartis AG (Advanced Accelerator Applications, S.A.)
  • 分析師觀點

第9章 章節

  • 參照資料
  • 調查方法
  • 關於Coherent Market Insights
目錄
  • Peptide receptor radionuclide therapy (PRRT) is a molecular therapy (radioisotope therapy) used for the treatment of cancer associated with neuroendocrine tumors (NETs). In PRRT, peptides (cell targeting peptide) combine with a small amount of radioactive material to produce radiopharmaceutical product called radiopeptide. PRRT can be also considered as personalized cancer therapy, as radiopeptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.

Market Dynamics

  • Rising number of cancer cases is a major factor driving growth of the peptide receptor radionuclide therapy (PRRT) market, globally. According to the American Cancer Society's 2019 report, in 2018, there were an estimated 17.0 million cases of cancer diagnosed across the world and 9.5 million deaths occurred due to cancer. For instance, according to the World Health Organization's 2018 report, cancer is the second leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. According to the same source, globally, around 1 in 6 deaths occur due to cancer.
  • Approvals for PRRT is expected to boost growth of the peptide receptor radionuclide therapy (PRRT) market during the forecast period. For instance, in September 2017, Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, received approval from European Medicines Agency (EMA) for its Lutetium (177Lu) Oxodotreotide (Lutathera) drug, which is indicated for gastroenteropancreatic neuroendocrine tumor.

Key features of the study:

  • This report provides in-depth analysis of the global peptide receptor radionuclide therapy (PRRT) market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 - 2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global peptide receptor radionuclide therapy (PRRT) market based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key player covered as a part of this study include Novartis AG (Advanced Accelerator Applications, S.A.)
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global peptide receptor radionuclide therapy (PRRT) market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global peptide receptor radionuclide therapy (PRRT) industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type:
  • Lutetium (Lu-177)-based
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Drug Type:
  • Lutetium (Lu-177)-based
    • By Disease Indication:
  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others
    • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Company Profile
    • Novartis AG (Advanced Accelerator Applications, S.A.)
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • "*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Mergers and Acquisitions
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis

4. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Lutetium (Lu-177)-based
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

5. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Disease Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Pancreatic - Neuroendocrine Tumor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Gastrointestinal Tract - Neuroendocrine Tumor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Peptide Receptor Radionuclide Therapy (PRRT) Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Novartis AG (Advanced Accelerator Applications, S.A.)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact